Overweight and Obese Volunteers.
Conditions
Keywords
obesity, overweight, chitosan, fungal chitosan, weight management
Brief summary
The prevalence of overweight and obesity is getting more and more important in developed as well as in emerging countries. It can be defined according to the degree of fat storage by measurement of fat mass. No clinical studies have been conducted so far for that intended use on KiOnutrime®-Cs, a fungal chitosan from the mycelium of non-genetically modified Aspergillus niger. KiOnutrime®-Cs has been recognized as substantially equivalent to animal chitosan. The purpose of this clinical trial is to determine if KiOnutrime®-Cs-containing medical device, which is a CE-marked medical device manufactured by KitoZyme, has an effect on body weight reduction after 3 months of intake in overweight and obese men and women. Furthermore, effects on anthropometric measurements, body fat mass percentage, serum lipids and safety parameters will be investigated.
Detailed description
The study duration per subject will be 3 months and 1 week maximum. Subjects will be screened at visit V1 and will start a 1-week run-in period, during which subjects will ingest 2 capsules of placebo 3 times a day. The subjects will then be randomized to receive the investigational medical device or placebo (1:1) for a 3 months product intake period.
Interventions
DEVICEKiOnutrime®-Cs
The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.
OTHERPlacebo
The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
Sponsors
Naturalpha
Kitozyme
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Males and females volunteers, able to read and write. * Subject with 25 ≤ Body Mass Index ≤ 35 kg/m². * Subject with a good physical condition based on the subject's interview and the clinical exam performed by the Investigator. * Subject with stable body weight (\< 5% variation) within the last 3 months prior to screening (based on interview). * Written informed consent provided prior to screening, after receiving and understanding the subject information. * Subject willing to lose weight. * Subject accepting to follow diet and lifestyle instructions throughout the study. * Subject willing to take study capsules three times a day for 3 months and 1 week and undergo other study-related procedures. * Registered with the French Social Security, in agreement with the French law on biomedical experimentation.
Exclusion criteria
* Smoker or former smoker having stopped within 2 months prior to screening visit. * Subject with a history of alcohol or drug abuse. * Subject with physical activity more than 3 hours per week. * Subject with any sensitivity or allergy to any of the products used within this clinical trial. * Subject with history of eating disorder (anorexia nervosa, bulimia nervosa). * Subject having used weight reduction treatments or products during the last 3 months prior to screening visit. * Subject with significant gastrointestinal disease (e.g. coeliac disease, pancreatitis), signs of intestinal obstruction or medical history of constipation. * Intake of chronic medication which could interfere with study parameters (weight, appetite, satiety, lipid blood levels, glycemia, gastrointestinal function), having an effect on digestion or absorption of nutrients, excepted oestroprogestative or progestative contraception started at least three months before the screening visit. * Female subject planning a pregnancy, pregnant or breastfeeding. * Female subject without efficient contraceptive method. * Subject with history of bariatric surgery. * Subject with known systemic disease such as cancer, human immunodeficiency virus (HIV) seropositivity. * Subject with type 1 or type 2 diabetes mellitus. * Subject with history of significant medical or surgical event requiring hospitalization during the 3 months prior the screening visit. * Subject having, had or scheduling to have an exam that uses barium, a radioisotope injection, or oral or intravenous contrast material within 2 weeks prior screening visit and during the study. * Participation to any other clinical trial simultaneously and/or within 1 month prior the screening visit. * Subject who has donated blood or blood products within the previous month prior to screening or who plans to donate blood or blood products at any time during the trial and in the 3 months following the end of the study. * Subject judged unlikely to comply with study product intake (screening compliance \< 80%) and with diet and lifestyle instructions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Body weight | 0 ; 30 ; 60 ; 90 days | Comparison of the reduction of body weight, from baseline (randomization visit) to end-point (3 months of treatment), between KiOnutrime®-Cs and placebo arms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body fat mass | 0 - 90 days | Mean changes from baseline (randomization visit) to end-point (3 months of treatment) in body fat mass percentage (fat mass, bone mass and lean mass measured by Dual-energy X-ray absorptiometry) between KiOnutrime®-Cs and placebo. |
| Hunger and satiety sensation | -7 ; 0 ; 30 ; 60 ; 90 days | Mean changes from baseline (randomization visit) to end-point (3 months of treatment) in hunger and satiety sensation via Visual Analog Scales measures between KiOnutrime®-Cs and placebo. |
| Serum lipids | 0 - 90 days | Mean changes from baseline (randomization visit) to end-point (3 months of treatment) in serum lipids (triglycerides and cholesterol) between KiOnutrime®-Cs and placebo. |
| Blood pressure | 0 ; 30 ; 60 ; 90 days | Mean changes from baseline (randomization visit) to end-point (3 months of treatment) in systolic and diastolic blood pressure between KiOnutrime®-Cs and placebo. |
| Electrolytic measurements and fat-soluble vitamins | 0 - 90 days | Mean changes from baseline (randomization visit) to end-point (3 months of treatment) in electrolytic measurements (Calcium, Magnesium, Sodium, Potassium) and fat-soluble vitamins (A, D, E) in plasma between KiOnutrime®-Cs and placebo. |
| Anthropometric measurements | 0 ; 30 ; 60 ; 90 days | Mean changes from baseline (randomization visit) to end-point (3 months of treatment) in anthropometric measurements (Body Mass Index, waist, hip and thigh circumferences) between KiOnutrime®-Cs and placebo. |
| Safety blood parameters | 0 - 90 days | Evaluation of the safety of KiOnutrime®-Cs through safety blood parameters measurements (urea, creatinine, glucose, Aspartate Aminotransferase and Alanine Aminotransferase). |
| Adverse events | Study duration | Evaluation of the safety of KiOnutrime®-Cs through adverse events recording. |
| Physical Activity score | -7 ; 0 ; 30 ; 60 ; 90 days | Mean changes from baseline (randomization visit) to end-point (3 months of treatment) in Physical Activity score (via Physical activity questionnaire). |
| Food recording | 0 ; 30 ; 60 ; 90 days | Estimation of total intake of food energy (calories), nutrients, and non-nutrient food components from foods and beverages that were consumed during a 3 days period prior to study visits from randomization to last visit. |
| Gastrointestinal tolerance | -7 ; 0 ; 30 ; 60 ; 90 days | Evaluation of the gastrointestinal tolerance of KiOnutrime®-Cs with a questionnaire at baseline (randomization visit), 30 days, 60 days and 90 days compared to placebo. |
Countries
France
Outcome results
None listed